Statins in coronary bypass surgery: rationale and clinical use.
Statin therapy prevents the first occurrence and recurrence of coronary events and reduces cardiovascular and general mortality in patients with coronary artery disease. These compounds modulate a variety of processes involved in the pathophysiology of arteriosclerosis and vascular graft disease by lipid-dependent and lipid-independent (pleiotropic) mechanisms. As a result, statins produce angiographic and clinical benefits in patients undergoing coronary bypass surgery. We review the present knowledge about the effects of statins on this pathologic condition and the evidence supporting an early treatment initiation.
Werba
José Pablo
JP
Atherosclerosis Unit, Centro Cardiologico Monzino IRCCS, University of Milan, Milan, Italy.
Tremoli
Elena
E
Massironi
Paola
P
Camera
Marina
M
Cannata
Aldo
A
Alamanni
Francesco
F
Biglioli
Paolo
P
Parolari
Alessandro
A
D001161:Arteriosclerosis / Q000503:physiopathology; D001026:Coronary Artery Bypass; D003327:Coronary Disease / Q000188:drug therapy / Q000503:physiopathology* / Q000601:surgery; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D012008:Recurrence
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors